Non-alcoholic fatty liver disease (NAFLD), recently renamed MASLD (metabolic dysfunction-associated steatotic liver disease), affects around 60 percent of women with PMOS according to a 2023 systematic review. It is one of the most underdiagnosed PMOS co-conditions because it is often silent in early stages and routine screening is not standard. Diagnosis is by elevated ALT or AST on bloodwork (often the first sign), liver ultrasound (showing fatty infiltration), or transient elastography (FibroScan) for fibrosis assessment. The treatment plan: the 30/30/40 PMOS dietary pattern (the same pattern that helps insulin resistance also reverses fatty liver), 5 to 10 percent weight loss if BMI is above 25, no alcohol or minimal alcohol, omega-3, and metformin or GLP-1 receptor agonists if metabolic markers warrant. NAFLD is largely reversible at the early stages. PMOS is the new name for PCOS as of 12 May 2026; NAFLD evidence is identical under both names.
Why NAFLD is more common in PMOS
The same insulin resistance that drives most PMOS symptoms also drives fat accumulation in the liver:
- Insulin resistance causes the liver to take up and store more fat from circulating triglycerides.
- The liver also produces more triglycerides under high insulin signaling (de novo lipogenesis).
- Fructose (from added sugars and excess fruit juice) is preferentially converted to liver fat.
- Chronic inflammation amplifies the fat-to-inflammation progression (NAFLD to NASH).
- Androgens may directly affect liver fat metabolism.
The 2023 systematic review of NAFLD in PCOS found prevalence of around 60 percent in women with PCOS compared to 20-30 percent in age-matched controls. PMOS women with insulin resistance, BMI above 25, or pre-diabetes have the highest rates.
Why NAFLD is often missed in PMOS
- Early NAFLD is silent. No symptoms until significant fibrosis develops.
- Liver enzymes are not always tested. Some doctors do not include ALT and AST in routine PMOS workups.
- "Normal" liver enzymes may not be optimal. ALT above 30 in women is often flagged as elevated by PMOS-informed clinicians; many labs do not flag until 40 or higher.
- Imaging is not standard. Liver ultrasound is reserved for confirmed elevated enzymes, missing early fatty change.
- NAFLD is associated with normal BMI in 20-25 percent of PMOS cases. "Lean NAFLD" is more common in PMOS than in the general population.
The NAFLD workup for PMOS
| Test | Standard lab range | PMOS interpretation |
|---|---|---|
| ALT (alanine aminotransferase) | Below 40 U/L | Above 30 U/L in women is often flagged as elevated by PMOS clinicians |
| AST (aspartate aminotransferase) | Below 40 U/L | Same threshold above 30 U/L |
| GGT (gamma-glutamyl transferase) | Below 50 U/L | Often elevated in NAFLD, also flags alcohol contribution |
| Alkaline phosphatase | Below 130 U/L | Less specific but part of the full panel |
| Triglycerides | Below 150 mg/dL | Often elevated in NAFLD. Triglycerides/HDL ratio above 3 is suggestive. |
| Fasting insulin and HOMA-IR | Insulin below 25 mIU/L, HOMA-IR below 2.0 | HOMA-IR above 2 supports NAFLD likelihood |
| FIB-4 calculator (online) | Below 1.3 low risk, above 2.67 high risk | Non-invasive fibrosis risk estimate from ALT, AST, age, platelets |
| Transient elastography (FibroScan) | CAP below 248 dB/m (no steatosis) | Best non-invasive test for fatty infiltration and fibrosis |
| Liver ultrasound | Normal echogenicity | Detects moderate to severe fatty infiltration; less sensitive for mild |
The PMOS NAFLD reversal plan
Step 1: 30/30/40 macros with calorie front-loading
The PMOS dietary pattern targets the same insulin resistance that drives NAFLD. The 2023 hepatology guidance on NAFLD lifestyle treatment closely mirrors PMOS dietary recommendations: moderate-carb, higher-protein, Mediterranean fats.
Step 2: 5 to 10 percent weight loss if BMI above 25
Weight loss is the most effective NAFLD intervention. The 2023 hepatology guidance:
- 3-5 percent weight loss: reduces hepatic steatosis (fat content)
- 5-7 percent weight loss: reverses NAFLD in many patients
- 7-10 percent weight loss: may reverse NASH (the inflammatory stage)
- 10+ percent weight loss: can reverse early fibrosis
For PMOS specifically, the 30/30/40 macro pattern at a 300-500 kcal deficit produces this weight loss while addressing the underlying insulin resistance.
Step 3: Eliminate or minimise alcohol
Alcohol amplifies NAFLD progression even at "moderate" intake. The 2024 EASL (European Association for the Study of the Liver) guidance recommends complete abstinence or minimal intake (below 1 drink per week) for any patient with confirmed NAFLD. For PMOS women without confirmed NAFLD but elevated risk, maximum 2-3 drinks per week is the realistic target.
Step 4: Reduce fructose intake specifically
Fructose (from added sugars, sugary drinks, fruit juice in excess) is preferentially metabolised to liver fat. Whole fruit is fine (the fibre slows fructose absorption); the focus is on liquid and added-sugar fructose. Sugary drinks are the single highest-leverage food category to reduce for NAFLD.
Step 5: Supplements with evidence for NAFLD
| Supplement | Dose | Evidence |
|---|---|---|
| Omega-3 (EPA+DHA) | 2-4g/day | Reduces liver fat by around 7-10% over 6 months per meta-analysis |
| Vitamin E | 800 IU/day | Recommended for biopsy-proven NASH per AASLD guidance. Some bleeding risk; specialist supervision recommended. |
| Inositol | 4g/day | Indirect benefit via insulin sensitivity; PMOS-specific evidence supportive |
| Berberine | 1,500mg/day | Reduces liver fat and improves liver enzymes in meta-analyses |
| Vitamin D3 | 2,000-4,000 IU if deficient | Low vitamin D associated with worse NAFLD outcomes |
Step 6: Metformin or GLP-1 if needed
Metformin (1,500-2,000mg/day) improves liver enzymes and insulin sensitivity. GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss and direct liver benefit; the 2024 FDA approval of resmetirom marks the first NAFLD-specific medication. For PMOS women with NAFLD and BMI 30+, GLP-1s are increasingly first-line.
Step 7: Exercise (strength training + walking)
Independent of weight loss, exercise reduces liver fat by 15-25 percent over 12-16 weeks of consistent training. Strength training 2-3x/week plus daily walking is the optimal combination for PMOS-NAFLD. HIIT can be added in moderation if cortisol tolerates.
The NAFLD timeline in PMOS
| Timeframe | What typically changes |
|---|---|
| 4-8 weeks | ALT and AST start to fall on consistent dietary intervention |
| 8-12 weeks | Liver enzymes often normalise. Triglycerides drop. Initial 3-5% weight loss in this window. |
| 3-6 months | Imaging shows reduction in hepatic steatosis at 5-7% weight loss. Most PMOS-NAFLD reverses in this window. |
| 6-12 months | Sustained reversal. Re-image to confirm. Maintain interventions long-term. |
What does not work for PMOS NAFLD
- "Liver detox" supplements (milk thistle, dandelion, charcoal). Mixed evidence at best; do not address the underlying insulin resistance.
- Juice cleanses. High fructose load is the opposite of what NAFLD needs.
- Strict carnivore or zero-carb diets. Can produce short-term improvements but lack long-term evidence and remove fibre-rich foods that help NAFLD.
- Ignoring "moderate" alcohol. Even 1-2 drinks per day amplify NAFLD progression in PMOS.
- Random vitamin E supplementation. Has evidence for biopsy-proven NASH at 800 IU/day but bleeding risk and lack of all-cause benefit mean it should be physician-supervised, not self-supplemented.
NAFLD by PMOS phenotype
| Phenotype | NAFLD risk and pattern | Priority intervention |
|---|---|---|
| Insulin-resistant (70%) | Highest NAFLD risk. Often paired with elevated triglycerides. | Full plan + weight loss + reduce fructose + omega-3 + metformin or GLP-1 |
| Adrenal (15%) | Lower NAFLD risk but possible. Often cortisol-driven liver fat. | Stress management + adequate calories + omega-3 |
| Post-pill (10%) | NAFLD may have been masked by COCs. Re-screen 3-6 months post-pill. | Standard plan, re-test liver enzymes 6 months post-pill |
| Inflammatory | Higher NASH (inflammatory NAFLD) risk. Often elevated GGT. | Anti-inflammatory diet, omega-3 3g, NAC, address gut |
Frequently asked questions
Is fatty liver more common in PMOS?
Yes. Around 60 percent of women with PMOS have non-alcoholic fatty liver disease (NAFLD) per the 2023 systematic review, compared to 20-30 percent in age-matched women without PMOS. Driven by the same insulin resistance that causes other PMOS symptoms.
How do I know if I have NAFLD with PMOS?
Get ALT, AST, GGT, triglycerides, fasting insulin tested. ALT or AST above 30 U/L in women warrants follow-up. The FIB-4 calculator (online, uses age, ALT, AST, platelets) estimates fibrosis risk. Liver ultrasound for moderate cases. Transient elastography (FibroScan) is the most useful non-invasive test for fatty infiltration and fibrosis.
Can NAFLD be reversed with PMOS?
Yes, largely. 3-5 percent weight loss reduces liver fat. 5-7 percent reverses NAFLD in many patients. 7-10 percent reverses NASH (the inflammatory stage). 10+ percent can reverse early fibrosis. The PMOS dietary pattern is the foundation.
What is the best diet for PMOS fatty liver?
The 30/30/40 PMOS pattern: 30 percent carbs, 30 percent protein, 40 percent fat, with calorie front-loading toward breakfast, 28-35g fibre per day, Mediterranean fats. Eliminate sugary drinks and added-sugar foods. Whole fruit is fine. Limit alcohol to minimal or none.
Should I take omega-3 for PMOS NAFLD?
Yes. 2-4g/day of EPA+DHA reduces liver fat by around 7-10 percent over 6 months in meta-analyses. PMOS women often have low omega-3 intake; adding 2g/day is a simple, evidence-backed intervention.
Can metformin help PMOS fatty liver?
Metformin improves liver enzymes and insulin sensitivity. Indirectly helpful for PMOS-NAFLD. Not approved specifically for NAFLD treatment but commonly continued in PMOS women with both conditions. GLP-1 receptor agonists have direct liver benefit and are increasingly preferred for PMOS-NAFLD with BMI 30+.
Do I need to stop drinking alcohol with PMOS NAFLD?
Yes or minimise to below 1 drink per week. The 2024 EASL guidance recommends complete abstinence for confirmed NAFLD. For PMOS women without confirmed NAFLD but elevated risk, 2-3 drinks per week or fewer is the realistic target. Alcohol amplifies NAFLD progression even at "moderate" intake.
How long does it take to reverse PMOS NAFLD?
Liver enzymes often normalise at 8-12 weeks on consistent intervention. Imaging shows reduced hepatic steatosis at 3-6 months with 5-7 percent weight loss. Most PMOS-NAFLD reverses in 6-12 months on the structured plan.
Build a PMOS plan that protects the liver
NAFLD is one of the most reversible PMOS co-conditions when caught early.
The same 30/30/40 PMOS pattern that helps insulin and androgens directly reduces liver fat. Take the free phenotype quiz for a PMOS meal plan built around your phenotype.
What to read next
- PMOS and pre-diabetes
- PMOS weight loss diet plan
- GLP-1s for PMOS
- PMOS lab tests explained
- PCOS is now PMOS: full renaming explainer
How this article was researched
Sources include the 2023 systematic review of NAFLD in PCOS, the 2024 EASL guidance on MASLD, the 2023 AASLD practice guidance, the 2024 FDA approval data on resmetirom, the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS, and meta-analyses on omega-3 and weight loss in NAFLD. PCOS was renamed PMOS on 12 May 2026; NAFLD evidence is unchanged. This article is informational and not medical advice. See our editorial standards.
Community Comments
Add a comment